Can TP53, TMB and TME Expand the Immunotherapy Benefit in Metastatic Colorectal Cancer?
A precision approach integrating TP53 status, TMB, and TME modulation could extend the immunotherapy benefit beyond MSI-H to TP53-mutated MSS mCRC; prospective first-line trials are warranted.
Authors
- Federica Mazzuca
- Eva Mazzotti (ORCID: https://orcid.org/0000-0001-8045-3410)
- Denise Drittone (ORCID: https://orcid.org/0009-0001-0846-1384)
- Monia Specchia (ORCID: https://orcid.org/0009-0001-9176-0149)
Institutions
- CTO Andrea Alesini (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Cancers
- Published
- 2025-12-13
- DOI
- https://doi.org/10.3390/cancers17243984
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00